Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eloralintide in Adults With Obesity or Overweight Without Type 2 Diabetes
NCT07321886Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Primary completion
- Mar 2028
- Modality
- Peptides
- Countries
- 15
01
Overview
A Phase 3 trial of eloralintide in obesity, Overweight, sponsored by Eli Lilly and Company. Started Feb 2026; status: recruiting.
02
Drugs
eloralintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07321886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07321886.